Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clinuvel Pharmaceuticals ( (AU:CUV) ) just unveiled an update.
CLINUVEL PHARMACEUTICALS LIMITED has issued 77,110 fully paid ordinary shares at no issue price, as announced in compliance with the Corporations Act 2001. This strategic move is part of the company’s ongoing efforts to strengthen its market position and ensure compliance with regulatory requirements, potentially impacting its operational capabilities and stakeholder interests.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
More about Clinuvel Pharmaceuticals
CLINUVEL PHARMACEUTICALS LIMITED is a global specialty pharmaceutical group focused on developing and commercializing treatments for genetic, metabolic, systemic, and life-threatening acute disorders, as well as healthcare solutions for specialized populations. The company is a pioneer in photomedicine and melanocortin peptides, with its lead therapy, SCENESSE®, approved for use in multiple regions including Europe, the USA, Israel, and Australia.
Average Trading Volume: 140,787
Technical Sentiment Signal: Sell
Current Market Cap: A$601.5M
Find detailed analytics on CUV stock on TipRanks’ Stock Analysis page.